Skip to content
Technology
Ultratouch
Engage

Enhance product access, automate patient outreach, and improve patient care

AccredComply

Stay on top of accreditation while caring for patients and accelerating growth

Ultratouch
Patient Management

Collect, organize, and catalog patient data for accreditation

LicenseComply

Accreditation and reaccreditation management platform

Ultratouch
Verify

Workflow-focused platform and complete prior authorization solution

RegComply

Regulation management platform for streamlining regulatory alerts

Ready to Talk? Contact Us
See How D2 Can Partner With Your Healthcare Organization

Mark Friederich

Vice President of Government & IDN Markets

Mark Friederich has 35 years of strategic launch and commercialization experience, in leadership roles, for more than 50 products. He also has 10 years of clinical experience in Trauma and Critical Care, providing an exceptional perspective toward healthcare strategy and tactics. Mark has been associated with D2 Consulting since 2010 helping create the Managed Markets initiative. He has also been a specialty reference consultant for 3 nationally recognized commercialization and business development firms, as well as a Managed Markets and Government regulatory resource for legal firms and investment organizations.

Mark's roles have been VP-level positions in Commercialization, Strategy, Global Market Access, and Reimbursement. He has held these positions for personalized medicine corporations, medical and commercial device manufacturers, and biotechnology/biopharmaceutical companies. His roles hold a common theme of coordinating payer engagement and reimbursement efforts in the US and UK while also directing Sales and Marketing teams.

30+ years of Medical & Specialty benefit experience
20+ years of Government/Federal experience - CMS, VA, DoD, FDA, Regulatory
5 years of international Payer experience - NICE, NHS, etc.
specialty hero 2
"Every day I'm dedicated to providing insight into peripheral topics; such as Diagnostics, NICE Guidelines, Cochrane and other 3rd party reviewers, NHS strategy, Clinical perspective, and more."
Mark Friederich